Tg Therapeutics (TGTX) Cost of Revenue (2021 - 2026)

Tg Therapeutics' Cost of Revenue history runs 6 years deep, the most recent figure standing at $33.5 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 115.62% year-over-year to $33.5 million; the TTM figure through Mar 2026 stood at $118.7 million (up 144.28% YoY), while the FY2025 annual figure was $100.7 million, up 161.69% from the prior year.
• Cost of Revenue for Q1 2026 stood at $33.5 million, down from $38.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $38.1 million in Q4 2025, with the low at $2000.0 in Q3 2022.
• The 5-year median for Cost of Revenue is $8.3 million (2024), against an average of $12.5 million.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue jumped 261700.0% in 2023, then jumped 96.07% in 2024.
• Tg Therapeutics' Cost of Revenue stood at $3000.0 in 2022, then surged by 261700.0% to $7.9 million in 2023, then surged by 96.07% to $15.4 million in 2024, then surged by 147.69% to $38.1 million in 2025, then declined by 12.14% to $33.5 million in 2026.
• Business Quant data shows TGTX's Cost of Revenue at $33.5 million in Q1 2026, $38.1 million in Q4 2025, and $28.1 million in Q3 2025.